Cambrex Corporation (CBM)
Cambrex Corporation R&D Expense: 2.358M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CBM R&D Expense Rankings
| Overall | 57th percentile | 746 of 1764 |
| Sector | 69th percentile | 126 of 413 in Healthcare |
| Industry | 74th percentile | 38 of 150 in Biotechnology |
CBM R&D Expense Range, Past 5 Years
| Minimum | 1.645M | Dec 2008 |
| Maximum | 3.534M | Dec 2007 |
| Average | 2.439M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these CBM related companies
CBM News
Morning Movers 05/04: (LF) (POWI) (MITK) (SPRD) Higher; (BODY) (INVN) (BONE) (CHEF) Lower
May 04, 11:31AM Street Insider
May 04, 11:31AM Street Insider
Listen to $CBM Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3fbQ
about 24 days ago by earningscast
about 24 days ago by earningscast
$CBM forms bearish "Top Triangle" chart pattern. http://stks.co/2umz
about 72 days ago by RecogniaEvents
about 72 days ago by RecogniaEvents
$CBM filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/2uQw
about 73 days ago by MarketBrief
about 73 days ago by MarketBrief
$CBM forms bullish "Symmetrical Continuation Triangle" chart pattern. http://stks.co/2ppD
about 75 days ago by RecogniaEvents
about 75 days ago by RecogniaEvents
Listen to $CBM Q4 2011 earnings call - live at 08:30 AM, ondemand after - http://stks.co/2HN8
about 111 days ago by earningscast
about 111 days ago by earningscast
Cambrex Corp. (CBM) Misses Q4 EPS by 2c, Offers Weak FY12 Sales Guidance
Feb 06, 5:13PM Street Insider
Feb 06, 5:13PM Street Insider
Cambrex to Present at UBS 22nd Annual Global Healthcare Services Conference
Feb 06, 3:34PM PR Newswire
Feb 06, 3:34PM PR Newswire
Cambrex to Announce Fourth Quarter 2011 Financial Results on February 6, 2012
Feb 02, 9:57AM PR Newswire
Feb 02, 9:57AM PR Newswire
With 60% of the St50 stocks in red today, best performers are: $AREX $CBM $CMN $NANO
about 118 days ago by StockTwits50
about 118 days ago by StockTwits50
$CBM http://stks.co/28WC good volume: 7.50 and I'll be all over this and breaks above 8.25 I'll grab it.
about 120 days ago by SteviniP
about 120 days ago by SteviniP
Cambrex to Announce Third Quarter 2011 Financial Results on November 3, 2011
Nov 01, 8:37AM PR Newswire
Nov 01, 8:37AM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBM | 7.08 | +0.00 | +0.00% | 209.71M |
| CBLI | 1.30 | +0.09 | +7.44% | 46.29M |
| CBL | 17.54 | -0.02 | -0.11% | 2.606B |
| CBKN | 2.16 | -0.04 | -1.82% | 185.33M |
| CBK | 1.32 | -0.06 | -4.35% | 47.52M |
| CBIN | 13.13 | +0.19 | +1.47% | 43.59M |
| CBI | 37.12 | -0.53 | -1.41% | 3.628B |
| CEA | 14.45 | -0.10 | -0.69% | 2.769B |
| CE | 40.78 | -0.03 | -0.07% | 6.395B |
| CDZI | 7.89 | -0.21 | -2.59% | 121.82M |
